Vera Therapeutics (NASDAQ:VERA) Trading 5% Higher Following Analyst Upgrade

Vera Therapeutics, Inc. (NASDAQ:VERA) shares were up 5% during trading on Tuesday after TD Cowen raised their price target on the stock from $73.00 to $78.00. TD Cowen currently has a buy rating on the stock. Vera Therapeutics traded as high as $42.72 and last traded at $42.1470. 404,335 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,266,493 shares. The stock had previously closed at $40.13.

A number of other research analysts have also commented on VERA. Bank of America upped their price target on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Guggenheim raised their price target on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $84.58.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00. Following the sale, the chief executive officer owned 198,244 shares in the company, valued at approximately $7,519,394.92. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 59,951 shares of company stock valued at $2,392,387. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics News Roundup

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
• Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
• Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
• Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VERA. GAMMA Investing LLC grew its position in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics during the 4th quarter valued at about $46,000. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics during the second quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics in the fourth quarter worth $71,000. Finally, Tower Research Capital LLC TRC increased its stake in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 1.2%

The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average price is $36.40 and its two-hundred day moving average price is $41.16. The stock has a market cap of $3.05 billion, a P/E ratio of -7.66 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) earnings per share. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.